Jiangsu Hengrui Pharmaceuticals Co Ltd

Hengrui’s new licensing deals for SHR6508 and PALI, combined with NMPA approval for a pivotal trial, set the stage for rapid progress in CNS and bone‑health therapeutics.

Jiangsu Hengrui expands national insurance coverage, adding oncology and targeted drugs to China’s catalog and innovation directory—boosting access, revenue, and market share.

Jiangsu Hengrui Pharma’s strategic gains from China’s expanded drug‑reimbursement policy, driving 4‑5% sales lift, high margins, and a strong outlook.

Jiangsu Hengrui Pharmaceuticals launches a self‑funded A‑share buy‑back (Aug 2025‑Aug 2026) and names Zhu Guoxin senior VP, boosting shareholder value and leadership stability.

Hengrui Pharmaceuticals shares rise modestly as the company focuses on high‑margin oncology pipelines, regulatory‑accelerated approvals, and sustainable growth in China’s pharma market.

Jiangsu Hengrui’s latest corporate and clinical updates: a Phase‑II injectable for membranous nephropathy, a new breast‑cancer partnership, and 2025 lock‑up expiry insights for investors and clinicians.

Jiangsu Hengrui Pharmaceuticals’ Q3 2023 report shows steady revenue & profit growth, a robust oncology pipeline, and a clear path to new approvals—making it a strong pick for investors focused on precision‑medicine innovation.

Jiangsu Hengrui Pharmaceuticals Co Ltd has secured a licensing agreement with Glenmark Specialty for the novel therapeutic agent SHR-A1811, a treatment for HER2-positive non-small cell lung cancer, which is expected to boost the company’s revenue an…

Jiangsu Hengrui Pharmaceuticals Co Ltd remains a strong and resilient player in the healthcare industry, driven by its commitment to innovation and strategic partnerships, despite recent market volatility.

Jiangsu Hengrui Pharmaceuticals, a Chinese healthcare giant, is experiencing unprecedented growth in innovative drug sales, with two of its medications, Revirulamin and Darzalex, driving a 60.66% share of its total revenue.